| Schedule of Segment Operating Expenses Including Segment Expenses, and Net Loss |
The Company's reportable segment total operating expenses, including significant segment expenses, and net loss for the three and six months ended June 30, 2026 and 2025, consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Therapeutics |
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Payroll and related |
|
$ |
48,543 |
|
|
$ |
25,193 |
|
|
$ |
90,584 |
|
|
$ |
45,950 |
|
Direct research and development - clinical trials |
|
|
15,633 |
|
|
|
12,636 |
|
|
|
44,329 |
|
|
|
24,630 |
|
Direct research and development - contract drug manufacturing |
|
|
15,742 |
|
|
|
23,498 |
|
|
|
46,197 |
|
|
|
33,040 |
|
Commercial planning |
|
|
15,057 |
|
|
|
3,822 |
|
|
|
23,040 |
|
|
|
6,986 |
|
Depreciation and amortization |
|
|
132 |
|
|
|
119 |
|
|
|
272 |
|
|
|
204 |
|
Other segment items* |
|
|
17,383 |
|
|
|
14,873 |
|
|
|
33,200 |
|
|
|
26,525 |
|
Total operating expenses |
|
|
112,490 |
|
|
|
80,141 |
|
|
|
237,622 |
|
|
|
137,335 |
|
Loss from operations |
|
|
(112,490 |
) |
|
|
(80,141 |
) |
|
|
(237,622 |
) |
|
|
(137,335 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
|
5,348 |
|
|
|
6,320 |
|
|
|
11,702 |
|
|
|
13,226 |
|
Interest expense |
|
|
(1,848 |
) |
|
|
(1,874 |
) |
|
|
(3,671 |
) |
|
|
(3,667 |
) |
Other segment items** |
|
|
(483 |
) |
|
|
(836 |
) |
|
|
(914 |
) |
|
|
(449 |
) |
Segment and consolidated net loss |
|
$ |
(109,473 |
) |
|
$ |
(76,531 |
) |
|
$ |
(230,505 |
) |
|
$ |
(128,225 |
) |
*Other segment items included in total operating expenses primarily consist of consulting and contractors, professional services, equipment and software, travel and entertainment, facilities, medical affairs, and corporate communications. **Other segment items included in net loss consist of currency exchange gains and losses and other income/expense.
|